Pralsetinib bulk supplier for pharma manufacturers

Pralsetinib 100 mg Suppliers & Bulk Manufacturers

Available Forms: Capsules

Available Strengths: 100 mg

Reference Brands: Gavreto (USA/EU)

Pralsetinib is a selective RET (rearranged during transfection) kinase inhibitor used to treat cancers that harbor RET gene fusions or mutations. It is administered orally and represents a targeted therapy for certain non-small cell lung cancers and thyroid cancers with RET alterations.

Ask About Access

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Pralsetinib? List it or send an offer →

Product Description:

Pralsetinib selectively inhibits RET, a kinase that becomes cancer-driving when its gene is fused to another or mutated at a point. Selectivity is the advance here. Earlier multi-kinase drugs with incidental RET activity, such as cabozantinib and vandetanib, could never be dosed high enough to suppress RET properly because their off-target effects on VEGF receptors caused hypertension and bleeding first. A clean RET inhibitor reaches full target coverage at a tolerable dose.

It is used for RET fusion-positive non-small cell lung cancer, RET fusion-positive thyroid cancer and RET-mutant medullary thyroid cancer, taken orally on an empty stomach. Response rates are high and durable, including in the brain. Adverse effects include hypertension, transaminase elevation, neutropenia, anaemia, constipation and musculoskeletal pain; pneumonitis, haemorrhage and impaired wound healing are less common but serious, and treatment is interrupted around surgery.

Sourcing notes. Originator product, on patent, with approval status varying by territory — confirm before quoting. Requires RET fusion or mutation testing, generally by next-generation sequencing, so the destination market needs that capability. The patient population is small but treatment is long. Oral capsules, room temperature.

How Pralsetinib is supplied today, and licensing ahead of patent expiry

Pralsetinib is a patented innovator medicine. Where its patents are in force, which today includes most major markets, it can only be supplied by the originator or its licensees, through the routes below. Patents do expire, though, and generic development and licensing deals for post-patent markets start years in advance. If you are developing Pralsetinib, hold a dossier for it or want to license it, talk to us.

Named-patient import Where a patient needs the product in a market where it is not registered, named-patient import is the lawful route. It requires the treating physician's documentation and authorisation from the destination regulator. We handle this pathway. Named-patient access

Authorised distribution For registered markets, supply runs through the manufacturer's authorised distribution channel. We can identify the authorised route for your market and tell you whether the product is registered there at all. Innovator sourcing

A genericised alternative Where the clinical requirement is the drug class rather than this specific molecule, there is often an off-patent alternative that is faster to register and materially cheaper. Tell us the indication and target market and we will say plainly whether one exists. Discuss alternatives

Licensing and generic development Patents expire country by country, and in many countries development and dossier filing can start before expiry under research and regulatory-review exemptions. We connect manufacturers developing this molecule, dossier holders, licensees and tech-transfer partners for markets where it is, or will become, off-patent. Partner on this molecule

Ask about Pralsetinib supply →

Back to Listing

Frequently Asked Questions

Pralsetinib is used for the treatment of non-small cell lung cancer (NSCLC) and thyroid cancers that have a rearranged during transfection (RET) gene alteration. It works as a selective RET kinase inhibitor, blocking the activity of abnormal RET proteins that drive cancer cell growth.

Pralsetinib is made from the active ingredient pralsetinib, a small-molecule tyrosine kinase inhibitor specifically designed to target RET fusion–positive or RET-mutant cancers.

The trade name of Pralsetinib is Gavreto.

Pralsetinib (Gavreto) is developed and marketed by Blueprint Medicines in collaboration with Genentech (a member of the Roche Group).

The generic name is Pralsetinib.

The brand name is Gavreto.

Pralsetinib is manufactured in the United States and Switzerland by Blueprint Medicines and Roche facilities following international regulatory standards for oncology drugs.

Gavreto (Pralsetinib) is developed and sold by Rigel Pharmaceuticals in the US, and by developed by Blueprint Medicines. PharmaTradz handles enquiries for authorised supply of the originator product, named-patient import where it is not registered, and licensing or development work ahead of patent expiry.